

Ref: STEX/OUTCOME/2024-25

Date: 13.08.2024

BSE Limited 25th Floor Phiroze Jeejebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
--	--

Sub. : Outcome of Board Meeting

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024, were approved by the Board of Directors of the Company at its meeting held today at 2:00 P.M. and concluded at 03:00 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- a) The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024; and
- b) Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter.
- c) Approved draft Annual Report for the financial year 2023-24.
- d) The 31st AGM of the Company will be held on Thursday the September 26, 2024 at 12.00 Noon through Video Conference (VC)/ Other Audio-Visual Means (OAVM) facility.

Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Thursday, September 19, 2024 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialized form) to cast their vote electronically from Monday, September 23, 2024 to Wednesday, September 25, 2024.

In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Re. 1 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2023-24. The aforesaid register will remain close from Thursday, September 19, 2024 to Wednesday September 25, 2024 (both days inclusive)

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

We request you to take the same on record

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2024, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS44157



MEDICAMEN BIOTECH LIMITED



Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th June 2024

PART I

Particulars	Standalone						Consolidated			
	Three Month period Ended			Year Ended			Three Month period Ended		Year Ended	
	30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited	31.03.2023 Unaudited	30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited	
1	Income from operations									
(a) Net Sales / Income from operations	4,148.17	4,500.73	4,050.34	17,238.62		4,304.86	4,731.95	4,194.31	17,930.62	
(b) Other Income	57.52	54.31	37.92	230.26		58.63	56.62	37.92	232.57	
(c) Total Revenue	4,205.69	4,555.04	4,088.26	17,468.88		4,363.49	4,788.57	4,232.23	18,163.19	
2	Expenses									
a) Cost of Material Consumed	2,142.37	2,264.52	2,581.84	10,469.80		2,166.57	2,182.33	2,610.85	10,469.80	
b) Purchase of Goods Traced	-	-	-	-		-	-	-	-	
c) Changes in inventory of Finished Goods and Work in Progress	237.71	55.62	(524.06)	(1,331.70)		242.61	177.29	(524.14)	(1,210.03)	
d) Employees Benefits Expenses	547.87	588.02	524.65	2,211.84		783.55	839.21	656.39	3,006.58	
e) Finance Cost	67.85	186.68	95.65	437.71		70.57	188.69	95.65	439.72	
f) Depreciation and Amortisation Expenses	174.21	177.31	167.97	700.84		177.03	177.44	169.08	709.32	
g) Other expenses	734.17	910.38	726.88	3,291.60		767.53	958.05	756.07	3,440.24	
Total Expenses	3,904.18	4,182.53	3,572.93	15,780.09		4,207.86	4,523.01	3,763.90	16,855.63	
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)									
Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	301.51	372.51	515.33	1,688.79		155.63	265.56	468.33	1,307.56	
4	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)									
Tax Expenses	83.56	79.12	124.62	421.69		83.56	79.12	124.62	421.69	
Current Year MAT Credit Entitlement	-	(16.92)	(50.99)	(62.70)		(7.80)	(17.60)	(50.99)	(63.53)	
Deferred Tax Liability	75.76	62.20	73.63	358.99		75.76	61.52	73.63	358.16	
5	Total Tax Expense									
Net Profit / Loss for the period from Continuing operation (5- 6)	225.75	310.31	441.70	1,329.80		79.87	204.04	394.70	949.40	
6	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)									
Tax Expenses	83.56	79.12	124.62	421.69		83.56	79.12	124.62	421.69	
Current Year MAT Credit Entitlement	-	(16.92)	(50.99)	(62.70)		(7.80)	(17.60)	(50.99)	(63.53)	
Deferred Tax Liability	75.76	62.20	73.63	358.99		75.76	61.52	73.63	358.16	
7	Total Tax Expense									
Net Profit / Loss for the period from Continuing operation (5- 6)	225.75	310.31	441.70	1,329.80		79.87	204.04	394.70	949.40	

Particulars	Standalone				Consolidated			
	Three Month period Ended		Year Ended		Three Month period Ended		Year Ended	
	30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited	30.06.2024 Unaudited	31.03.2024 Audited	30.06.2023 Unaudited	31.03.2024 Audited
8 Other Comprehensive Income Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	225.75	310.31	441.70	1,329.80	79.87	204.04	394.70	949.40
10 Net Profit /Loss attributable to a) Controlling Interest b) Non-controlling Interest								
10 Paid up equity share capital (Rs. 10/- per share)	1,271.46	1,271.46	1,265.11	1,271.46	1,271.46	1,271.46	1,265.11	1,271.46
11 Earning Per Share (Rs.) Basic	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50
Diluted	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50

NOTES :

- 1 The Un-audited financial results for the quarter ended 30.06.2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.08.2024
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- 5 Limited Review has been carried out by the Statutory Auditors for the above period.
- 6 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 13.08.2024

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

**The Board of Directors,
Medicamen Biotech Ltd.**
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended on June 30, 2024 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants


Qimat Rai Garg
Partner
(Membership Number: 013152C)
UDIN: 24080857BKFFZZ3689

Place: Gurugram
Date: 13.08.2024

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

**The Board of Directors,
Medicamen Biotech Ltd.**
1506, Chiranjiv Tower, 43
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended on June 30, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited (the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statements includes the Group's share of net profit/(loss) after tax of Rs. (1.45) Crores for the quarter ended on June 30, 2024, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

**For Rai Qimat & Associates
Chartered Accountants**



**(Membership Number: 013152C)
UDIN: 24080857BKFFZZ3689**

**Place: Gurugram
Date: 13.08.2024**